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Platinum-DNA adduct formation in leucocytes of
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Summary Platinum (Pt)-DNA adducts were measured in peripheral blood leucocytes (PBLs) from 24 children with solid tumours after
standard cisplatin and/or carboplatin treatment. The relationship between Pt-DNA adduct levels and pharmacokinetics of cisplatin and
carboplatin was investigated. Adduct measurements were performed bycompetitive enzyme-linked immunosorbent assay(ELISA) and plasma
unbound Pt concentrations were measured by atomic absorption spectrophotometry (AAS). There was considerable interindividual variation in
Pt-DNA adduct level that was weakly correlated (r2 = 0.32) with the area under the unbound drug concentration vs time curve (AUC) at 6 h
afterthe start of cisplatin infusion, indicating thatthe variation in Pt-DNA adduct levels was primarily determined byfactors otherthan AUC. No
clear relationship between AUC and adduct levels was seen at 24 and 48 h after cisplatin or at 6, 24 or 48 h after carboplatin. Carboplatin
produced lower levels of immunoreactive adducts than did cisplatin (1.3±0.6 nmol Pt g-1 DNA vs 3.2 ± 1.7 nmol Pt g-' DNA), despite a 20-fold
higher unbound drug AUC for carboplatin (8.0 ± 3.5 mg ml-' min vs 0.4 ± 0.2 mg ml-' min). This study demonstrates that, after cisplatin and
carboplatin treatment the drug-target interaction is determined by both pharmacokinetic and, predominantly, cellular factors. Intrinsic
differences between the two complexes, primarily reactivity, probably explain the lower adduct levels observed aftercarboplatin treatment.
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Cisplatin and carboplatin are widely used in the treatment of solid
tumours in childhood (Pinkerton et al, 1986; Pearson et al, 1992;
Doz and Pinkerton, 1994). The activity and toxicity of cisplatin
andcarboplatin depend upon bothpharmacokinetic andpharmaco-
dynamic factors. A number of clinical pharmacokinetic-
pharmacodynamic relationships have been described for cisplatin
(Campbell et al, 1983; Reece et al, 1987; Thomas et al, 1994) and
carboplatin (Egorin et al, 1984; Newell et al, 1987, 1993; Harland
et al, 1991; Horwich et al, 1991; Sorensen et al, 1991; Jodrell et al,
1992), and interpatient variability in tumour response to and/or
tolerance of platinum (Pt)-complex therapy may relate to plasma
levels more closely than to dose. Therefore optimum treatment
with Pt drugs may necessitate adjustment for interindividual phar-
macokinetic differences. Renal function-based dosing formulae
have been developed for carboplatin administration to children
(Marina et al, 1993; Newell et al, 1993; Chatelut et al, 1996)
because carboplatin is cleared primarily by glomerular filtration.
Although pharmacokinetics is one determinant of the clinical
efficacy ofPtcomplexes, intracellularfactors are certain toplay an
additional role. Pt complexes exert their anti-tumour effect by
reacting with DNA (Roberts and Thomson, 1979; Sherman and
Lippard, 1987; Fichtinger-Schepman et al, 1995). The presumed
cytotoxic lesions are Pt-DNA intra- andinterstrand cross-links. To
perform measurements of Pt-DNA adduct levels in the clinical
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setting, a number of groups have developed highly sensitive
immunoassays (Poirier et al, 1982; Fichtinger-Schepman et al,
1985; Terheggen et al, 1988; Tilby et al, 1991). Preliminary
clinical results with immunoassays for Pt-DNA adducts support
the suggestion that adduct formation may relate to anti-tumour
activity. Specifically, Reed and colleagues (Reed et al, 1986, 1987,
1988, 1990) have reported that adduct levels in peripheral blood
leucocytes (PBLs) correlate with response in patients receiving
either cisplatin- or carboplatin-based therapy. A major limitation
of these studies is that the influence ofpharmacokinetic variation
was not investigated. This parameter has been examined in a
recent study by Schellens et al (1996) that revealed a correlation
between area under the plasma free-drug concentration vs time
curve (AUC) and area under the leucocyte Pt-DNA adduct level
vs time curve for the first course of cisplatin treatment in a group
ofadultpatients with solid tumours. No studies have been reported
conceming the molecular pharmacodynamics of cisplatin or
carboplatin in paediatric patients.
The experiments described in this paper examine, for the first
time, the relationship between the pharmacokinetics of cisplatin
and carboplatin, and Pt-DNA adduct formation, in PBLs of chil-
dren with cancer. Pt-DNA adduct levels were analysed with the
following aims: (1) to compare Pt-DNA adducts levels produced
by cisplatin and carboplatin in PBLs ofchildren; and (2) to inves-
tigate the relationship between drug exposure (dose and AUC) and
the levels ofPt-DNA adducts in PBLs.
*Present address: Department ofPharmacy, University ofManchesterMl3 9PL, UK
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MATERIAL AND METHODS
Patients and clinical procedure
Twenty-four children and adolescents (6 female patients, 18 male
patients), receiving cisplatin and/or carboplatin at the Children's
Cancer Unit of the Royal Victoria Infirmary (Newcastle, UK) were
entered into this study. The study protocol was approved by the
Newcastle Health Authority and University ofNewcastle upon Tyne
joint ethics committee. All patients and/or their parents gave
informed consent before entering the study. The age, sex, body
weight, surface area, diagnoses and concomitant chemotherapy for
the patients are listed in Table 1. Thirty-five courses of treatment
when patients received Pt drugs were studied (18 doses of carbo-
platin ranging between 340 and 1000 mg m-2, 17 doses of cisplatin
ranging between 50 and 120mg m-2) in combination with other
agents. Cisplatin was administered as a 24-h infusion in normal
saline with hydration. Carboplatin was diluted in 100 ml ofdextrose
solution (5%, w/v) and infused over 60 min. In most cases, the doses
ofcarboplatin and cisplatin administered were based on surface area.
Blood samples (3 ml) were obtained from a central line immediately
before and at the mid and end points ofthe infusion, and at 0.25,0.5,
1, 2, 4, 8 and 24 h after the end of the infusion of carboplatin. For
cisplatin, blood samples were collected before and 0.5, 1.0, 2.0,4.0,
6.0 and 18.0 h into infusion, at the end of infusion and at 0.5, 1.0,
1.5, 2.0 and 24.0 h after the end of infusion. Blood samples were
centrifuged at lOOOg,4°C for 10 min. Plasma was then removed and
1 ml was placed in an Amicon Centrifree micropartition unit
30 000 MW cut-off (Amicon, Stonehouse, UK) and centrifuged at
2000g 4°C for 10 min. Plasma ultrafiltrate and plasma were stored
at-20°C (< 1 month) untilanalysed forpharmacokinetic studies. For
Pt-DNA adductanalysis, an additional 10 ml ofblood was collected
into plastic tubes, containing potassium EDTA (20 mg per tube),
immediately before treatment with carboplatin or cisplatin and at 6,
24 and 48 h after beginning the infusion ofcisplatin or carboplatin.
These samples were stored at-80°C (< 1 month) until analysis.
Pt-DNA adduct level measurement
Blood samples (10 ml) were thawed out gradually on ice over a
period of 2-4 h. The blood was transferred to 50-ml tubes and
each blood tube was rinsed out with 5-10 ml of sterile distilled
water and the washings added to the 50-ml tube. Distilled water
was added up to the 25-ml mark on the tube and blood lysis buffer
added up to the 50-ml mark. The tube was gently inverted once or
twice, placed on ice for 30 min with further occasional mixing,
then centrifuged at 2000g for 15 min (4°C) and the supematant
removed down to 5 ml using a pastette. Tubes were refilled with
lysis buffer to 50 ml, placed on ice for 10 min with further occa-
sional inversion, and centrifuged as described above. The super-
natant was poured off, leaving behind 0.1-0.2 ml of residue. The
leucocyte cell pellet was vortex mixed to produce a suspension
that was either stored (-20°C) or immediately processed further.
The method for the isolation of cellular DNA from frozen pellets
of cells was as described previously (Tilby et al, 1991). Pt-DNA
adduct levels were determined using a monoclonal antibody
(ICR4) specific for cisplatin-induced adducts on DNA (Tilby et al,
1991). The competitive ELISA method used was as described in
detail previously (Tilby et al, 1987, 1991).
Table 1 Characteristics of children studied
Number Age Sex BW SA DG Other Cisplatin Carboplatin
(years) (kg) (m2) drugs dose dose
(mg m-2) (mg m-2)
1 9.3 M 19.3 0.82 OS DOX 100
2 9.1 M 38.8 1.26 OS DOX 100
3 19.3 F 68.8 1.75 OS DOX 100
4 4.6 F 19.1 0.78 OS DOX 100
5 17.5 M 75.5 1.92 MFHC DOX 100
6 5.4 F 18 0.78 MOC DOX/CPA 100
7 13.5 F 42.7 1.63 NE DOX 120
8 18.5 M 62.7 1.8 OS DOX 100
9 1.2 M 8.9 0.41 BSG VCR 580
10 4.7 M 17.6 0.72 ME VCR 500
11 11.6 M 34.5 1.13 PT VP16 560
12 3.3 M 13.2 0.58 RPR 400
13 1.8 F 10.3 0.5 GL VCR 560
14 16.2 M 53.3 1.57 PRPD VP16 600
15 15.4 M 43.9 1.38 PT VP16 500
15 1000
16 4.1 F 13.5 0.6 NB COJEC 80 750
17 7.5 M 22.3 0.94 NB COJEC 80 700
18 *0.5/0.7 M *8.4/9.2 *0.42/0.44 GL 50 400
19 3.8 M 13.7 0.6 NB COJEC 80 750
20 5.3 M 16.9 0.75 NB COJEC 80 700
21 1.7 M 11.5 0.52 NB OPEC/OJEC 80 500
22 18.3 M 43.2 1.4 NB COJEC 80 700
22 780
23 2.4 M *12.7/14.3 *0.57/0.61 NB OPEC/OJEC 100 340
24 1.8 M *13.5/13.8 *0.54/0.55 NB OPEC/OJEC 80 500
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Figure 1 Pt-DNA adduct profiles in PBL of children with cancer after
(A) a 24-h infusion of cisplatin or (B) a 1-h infusion of carboplatin. A-A,
V-V, Two children who had adduct measurements after two courses.
(C): Combined Pt-DNA adduct profiles from the cisplatin and carboplatin
groups (mean ± s.d.). *P < 0.05 compared with Oh; **P < 0.05 compared
with carboplatin at 24 h
Pharmacokinetic studies
Plasma ultrafiltrates prepared after cisplatin or carboplatin treatment
were analysed for unbound Pt content by atomic absorption spec-
trophotometry (AAS) using a graphite tube atomizer (PU9100, ATI
Unicam, Cambridge, UK) (Ghazal-Aswad et al, 1996). The typical
sensitivity ofthe AAS was an absorbance ofapproximately 0.1 units
when 20p1 of a standard solution (58ng Pt ml-1, in 0.1 M
hydrochloric acid) was analysed, i.e. analiquotcontaining about 1 ng
of Pt. Each sample was analysed twice and the intra- and interassay
coefficients of variation for a quality assurance sample had to be
<10% for an assay to be valid. The samples were diluted with 0.1 M
hydrochloric acid to achieve concentrations that were within the
range ofthe standard curve. All drug concentrations described in this
paperreferto the intactcisplatin orcarboplatin equivalent. The AUC
calculated using the trapezoidal rule (Gibaldi and Perrier, 1982) was
used forthe interpretation ofplasmadisposition kinetics.
RESULTS
An attempt was made to measure Pt-DNA adduct levels in every
patient receiving either cisplatin or carboplatin as part of the
studies described in this paper. Unfortunately, in some cases, inad-
equate quantities of DNA were obtained for measurement of
adduct levels or, alternatively, the patient was too young to allow
the collection of sufficient blood. Pt-DNA adduct levels were
analysedby competitive ELISA. Ithas been shownpreviously that
the reaction of DNA with cisplatin in pure solution gives adducts
with the same immunoreactivity as those produced when the
reaction with DNA has taken place in cells (Tilby et al, 1991). To
define the reliable limit of detection of the ELISA for blood
samples, a series of DNA samples prepared from blood taken
before treatment were tested. Thek-values (IC50) forDNA samples
from pretreatment PBLs of children (n = 12) were 3.2 ± 1.0 ig
DNA per assay well, corresponding to an apparent level of
immunoreactive Pt-DNA adducts of 0.6 ± 0.2 (mean ± sd) nmol
Pt g-' DNA. This immunoreactivity was due to interference or the
immunological cross-reaction of high concentrations of control
DNA in the assay, as reported previously (Tilby et al, 1991).
Therefore, it was concluded that 1.0 nmol Pt g-' DNA was the
reliable limit for adduct detection, i.e. the mean value for control
pretreatment samples plus twice the S.D.
Pt-DNA adduct levels following cisplatin administration
and their relationship to cisplatin dose and
pharmacokinetics
Seventeen patients were investigated from whom blood was
removed before drug administration and 6, 24 and 48 h after the
start of the 24-h infusion of cisplatin. These children received
80-120 mg cisplatin m-2 except patient 18 who received
50 mg m-2. In all patients, DNA adduct levels were higher at 24 h,
ie. at the end of infusion (< 1-5.9 nmol Pt g-1 DNA) than at 6 h
(< 1-3.2 nmol Pt g-' DNA). Figure 1A shows that for all patients,
a similar pattern of adduct levels was observed, with the highest
level at 24 h in all patients except patient 23, in whom the highest
adduct level was at the 48-h point. Adduct levels declined after
the end ofthe infusion, the average having decreased to about half
the level seen at 24 h during the 24 h after the end of the cisplatin
infusion.
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Figure 2 Relationship between cisplatin dose and increase in apparent
Pt-DNA adduct level over the level in the pretreatment sample 6, 24 and 48 h
after the start of a 24 h infusion of cisplatin. Points are individual patients
The results from the 17 children show considerable interindi-
vidual variation. In an attempt to explain this variation, Pt-DNA
adduct levels 6, 24 and 48 h after administration ofcisplatin were
studied for their dependence on either the cisplatin dose or the
AUC ofunbound cisplatin in plasma. However, there was no clear
relationship between adduct levels and cisplatin dose (Figure 2).
As shown in Figure 3, there was a weak linear correlation between
adduct levels 6 h after the start ofcisplatin infusion and the 0-6 h
unbound cisplatin AUC (r2 = 0.32, P < 0.05), indicating that the
unbound cisplatin AUC at early times was a significant determi-
nant of the formation of Pt-DNA adducts. In contrast, there was
no linear correlation between adduct levels and the unbound
cisplatin AUC at 24 h, i.e. at the end of infusion, and only a very
weak relationship at 48 h (r2 = 0.22). Spearman's rank correlation
analysis indicated a significant correlation only for the 6- and 48-h
time points (P = 0.009 and 0.014 respectively).
1 48 h r2=0.22
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Figure 3 Relationship between free cisplatin AUC and increase in apparent
Pt-DNA adduct level over the level in the pretreatment sample 6, 24 and 48 h
after the start of a 24 h-infusion of cisplatin. Points are individual patients and
lines are linear regression lines fitted without constraint to the origin. The
fitted equations were y= 13.9x+ 0.0426 hand y= 1.9x+ 0.1948 h
Pt-DNA adduct levels after carboplatin administration
and their relationship to carboplatin dose and
pharmacokinetics
Pt-DNA adduct levels were studied in the DNA of PBLs from 16
children who received carboplatin treatments of 340-1000 mg
carboplatin m-2 as a 1-h infusion. Figure lB shows overall data for
the apparent Pt-DNA adduct levels for 18 courses (16 patients).
The mean immunoreactivity of the DNA increased 2.8-fold
between pretreatment and 5 h after the end ofinfusion. Thereafter,
immunoreactivity remained at steady-state until 48 h after the start
of the carboplatin infusion. Overall, the Pt-DNA adduct levels
after carboplatin were low and frequently at or below the limit of
reliable quantification ofthe ELISA (1 nmol Pt g-' DNA).
The increases in immunoreactivity at 6, 24 and 48 h over
pretreatment levels were calculated. Figures 4 and 5 indicate that
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Figure 4 Relationship between carboplatin dose and increase in apparent
Pt-DNA adduct level over the level in the pretreatment sample 6, 24 and
48 h after the start of a 1-h infusion of carboplatin. Points are individual
patients
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Figure 5 Relationship between free carboplatin AUC and increase in
apparent Pt-DNA adduct level over the level in the pretreatment sample 6,
24 and 48 h after the start of a 1-h infusion of carboplatin. Points are
individual patients
there were no clear relationships between apparent Pt-DNA
adduct levels and either carboplatin dose or AUC. This was
confirmed by the lack of significance in Spearman's rank correla-
tion analyses, except for the small set of data available for the
48-h timepoint (Figure 4, P = 0.03). This suggests thatinterpatient
differences in immunoreactivity after carboplatin were caused
predominantly by factors other than dose or pharmacokinetic vari-
ability.
Comparison of Pt-DNA adduct levels produced by
cisplatin and carboplatin
Both carboplatin and cisplatin produced Pt-DNA adducts in a
time-dependent manner (Figure IC). Levels of immunoreactive
Pt-DNA adducts appeared to approach a maximum value at the
end ofthe 24-h cisplatin infusion. However, after a 1-h infusion of
carboplatin, immunoreactive Pt-DNA adduct levels were lower
and did not follow a clear time course. The mean binding of Pt to
the DNA of PBLs from children treated with carboplatin at
340-1000 mg m-2 was 1.3 nmol Pt g-' DNA, 24 h after the start of
the infusion. In contrast, DNA extracted from PBLs of children
who had received 50-120 mg m-2 cisplatin showed a mean
Pt-DNA binding of 3.2 nmol Pt g-I DNA at the end of the 24-h
infusion. Thus, although a 20-fold higher unbound drug exposure
(AUC) was achieved aftercarboplatin treatment (8.0 ± 3.5 mg ml
min vs 0.4 ± 0.2 mg ml-1 min), the peak level of immunoreactive
Pt adducts on the DNA of PBLs from children treated with
cisplatin was 2.5-fold greater (3.2 ± 1.7 nmol Pt g-1 DNA vs
1.3 ± 0.6 nmol Pt g-' DNA).
Effects of the DNA extraction method
During the courseofthis work, Maetal (1995) reportedthatextrac-
tion of DNA from frozen whole-blood samples resulted in higher
adduct levels than were observed when white blood cells were
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Figure 6 Model for the proposed reaction of cisplatin and carboplatin with
DNA
isolated from the fresh blood sample before freezing. This effect
was attributed to the reaction ofcisplatin present in the whole blood
with DNA in cells that had become permeabilized. The extraction
method used in the present work differs in detail to that tested by
Ma et al (1995), and certain aspects of the data presented are not
consistent with the possibility that the adduct levels were influ-
enced to a large extent by carry-over of active drug in the blood
sample. For example, the levels of adducts were lower at 6 h after
the start of cisplatin infusion than at 24h, despite the fact that the
concentration of free drug was essentially equal at these two time
points. However, to verify that the present results were not influ-
enced by carry-over of active drug, cisplatin and carboplatin were
added to samples offreshly obtained blood. The samples were then
divided immediately and either frozen and extracted by our stan-
dard method, or processed according to the buffy coat method of
Ma et al (1995). DNA extracted from frozen whole blood
containing 1 JUM cisplatin (representing the mean concentration of
free drug present in blood samples removed for adduct measure-
ments) was not significantly more immunoreactive than DNA from
blood not treated with platinum complexes. DNA extracted from
frozen whole blood containing 5 gM cisplatin (twofold higher than
was present in any blood sample taken for adduct measurements)
showed a slight increase in immunoreactivity but this only just
attained the level of significance of 1 nmol Pt g-1 DNA. No blood
sample taken for the measurement of DNA adducts induced by
carboplatin was taken until at least 5 h after the end of carboplatin
infusion and therefore, unlike the situation with cisplatin, the level
of reactive drug had declined markedly before removal of the first
sample for measurement of adducts. DNA extracted from whole-
blood to which carboplatin had been added to give concentrations
up to 50 gM (five times the maximum free drug concentration
present in blood samples removed for adduct measurements) was
not significantly more immunoreactive than DNA from blood not
treated with platinum complexes. None of the blood samples
processed by the buffy coat method of Ma et al showed detectable
increases in immunoreactivity above the control DNA.
DISCUSSION
The objectives of this study were to describe Pt-DNA adduct
formation in PBLs of children with cancer, and to investigate the
relationship between adduct levels and both the doses andpharma-
cokinetics of cisplatin and carboplatin. Reed et al (1990) have
reported that in a group of relapsed ovarian cancer patients the
extent of Pt-DNA adduct formation in white blood cells (WBC)
DNA was directly related to disease response after treatment with
either single-agent cisplatin or carboplatin. Furthermore, adduct
levels in leucocytes were more closely related to disease response
than other previously identified prognostic variables, including
patient performance status, stage of disease, response to previous
treatment, total previous Pt drug dose, age, histological type and
grade. Analogous observations were reported for patients with
testicular cancer by the same group (Reed et al, 1988) and by
Fichtinger-Schepman et al (1990). More recently, in patients with
a variety of tumour types, Blommaert et al (1993) found that
immunohistological staining of buccal cells for carboplatin-
induced adducts was significantly higher in partial responders than
in non-responders. Measurement of PBL Pt-DNA adduct levels
by AAS also demonstrated higher levels in responding vs non-
responding patients (Parker et al, 1991) and it has been reported
that response to single agent cisplatin, or cisplatin plus etoposide,
was related to PBL adduct levels measured by AAS in a mixed
group of43 patients (Ma et al, 1994; Schellens et al, 1996). These
separate studies support the concept that there may be a 'parallel'
between malignant tumour tissues and normal cells, including
PBLs, in their capacity to form, repair, or otherwise retain
Pt-DNA adducts. However, as most of the above studies did not
include pharmacokinetic measurements, the possibility cannot be
excluded that the variation in adduct levels in PBLs was simply a
reflection ofpharmacokinetic variability. Indeed, in support ofthis
latter suggestion, the study described by Ma et al (1994) and
Schellens et al (1996) did show arelationship between both adduct
levels and cisplatin AUC, and AUC and response, as well as
adduct levels and response.
There were substantial differences in absolute adduct levels
between the above mentioned clinical studies. In addition to the
drug used, the dose administered and the pharmacokinetics, these
differences may be related to dosing schedules, assay method-
ology and/or other factors. The immunoassay used here, readily
detected adducts at the levels found in PBLs ofpaediatric patients
receiving conventional doses of cisplatin. Pt-DNA adduct levels
ranged up to 5.9 nmol g-I DNA, values much higher than those
determined by Reed (1990) (up to 0.4 nmol g-1 DNA), but similar
to those determined by Fichtinger-Schepman (1990) (up to
10 nmol g-I DNA) and Ma (1995) (mean values 13 and 7 nmol g-'
DNA). In the case ofcarboplatin, adduct levels were generally low
and were only just detectable by the ELISA. The low levels of
adducts found in the patients after carboplatin treatment could be
due to either lower levels ofPt-DNA binding or qualitative differ-
ences in the adducts formed by cisplatin and carboplatin. These
possibilities are discussed more fully below.
Levels of cisplatin adducts increased during the 24-h infusion
and then declined overthe next 24 h (Figures lA and C). Observed
levels of.carboplatin-induced adducts often increased between 6
and 24 h (Figure IB), despite the fact that the drug was only
infused over 1 h and that unbound drug was largely cleared from
the circulation by 6 h. Furthermore, between 24 h and 48 h after
infusion the observed levels of adducts showed no appreciable
reduction. This difference in time course of adduct level change
might be explained by the post-infusion conversion of monofunc-
tional carboplatin-DNA products into bidentate adducts (Figure 6).
Because of the much longer infusion time for cisplatin compared
with carboplatin, most ofthe initially formed cisplatin adducts had
a longer time period in which to complete any delayed second-arm
reactions before removal of the first, post-infusion blood sample.
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However, the main cause of the observed difference between the
drugs is likely to be the slower rate of the second-arm reaction for
carboplatin compared with cisplatin (Knox et al, 1986). Slow loss
of the cyclobutanedicarboxylato group from monofunctional
adducts on DNA and guanosine monophosphate was shown by
Knox et al (1986) and Frey et al (1993) respectively. The
immunoreactivity to ICR4 of the ultimate reaction products of
carboplatin with DNA was the same as the immunoreactivity of
cisplatin adducts (Tilby et al, 1991; B Peng et al, unpublished
data), although recent dataindicate slightdifferences in the distrib-
ution of adduct types formed by the two drugs (Fichtinger-
Schepman et al, 1995). The monoclonal antibody ICR4 was raised
againstcisplatin-DNA adducts andprobably does notrecognize the
monovalentcarboplatin-DNA adduct(Ghazal-Aswad etal, 1993).
In the presentstudy, afterthe administration of 'clinicallyequiv-
alent' doses ofcisplatin and carboplatin, carboplatin was found to
produce lower levels of immunoreactive Pt-DNA adduct than
cisplatin in PBLs. The average peak level of immunoreactive
adducts formed during cisplatin therapy was 2.5-fold higher than
that observed after carboplatin therapy despite the carboplatin
plasma AUC being 20-fold higher than the cisplatin AUC.
Cisplatin adduct levels decreased markedly during the 24 h after
the end of the drug infusion (Figure IC), possibly due to DNA
repair processes. The longer infusion ofcisplatin (24 h) compared
with carboplatin (1 h) provided greater opportunity for initially
formed adducts to be removed before the first post-infusion blood
sample was taken. This factor may have acted to reduce the
detectable levels of adducts formed by cisplatin and thereby
diminish the detected differences between the two drugs.
During the course of this work, Ma et al (1995) reported that
extraction ofDNA from wholeblood, as opposed to isolated white
blood cells, could result in elevated adduct levels that were attrib-
uted to the effects of carried over active drug present in the blood
sample. The data presented here were not significantly influenced
by this phenomenon, although cisplatin at concentrations higher
than were present in any of the blood samples taken for adduct
measurement did show a slight effect. Compared with the samples
studied by Ma et al, the concentrations ofcisplatin in the present
samples were probably lower because of the use of a 24 h-infu-
sion. This, together with slight differences in the extraction tech-
nique apparently avoided thepotentialdiscrepancyreportedby Ma
et al, however, our results indicated that this problem would
become significant at higher plasma concentrations of cisplatin
and are thereby consistent with the findings ofMa et al (1995).
Previous studies showing interpatient variation in Pt-DNA
adduct levels were summarized in the introduction. In the present
study, measurements have been made ofboth Pt-DNA adducts and
of unbound plasma drug levels. The results show that variation in
pharmacokinetics could account for only a small proportion ofthe
interpatient variation in adduct levels. Indeed, the only convincing
evidence for a relationship between drug plasma AUC and adduct
level was seen inpatients whoreceivedcisplatin treatment, where a
weak correlation between Pt-DNA adduct levels at 6 h and the
0-6 h cisplatin AUC was observed (Figure 3). Thus, cisplatin AUC
may be a determinant ofPt-DNA adduct levels atearlytime points.
At later time points (24 and 48 h), no clear relationship between
cisplatin AUC and adduct levels was seen in the present study. The
lack of a relationship at later time points could reflect the impact
of either removal of adducts (DNA repair) and/or the turnover
of PBLs on total blood Pt-DNA adduct levels. In the case of
carboplatin, there was no relationship between adduct level and
carboplatin AUC at any of the time points studied, which is in
agreement with the observation by Blommaert et al (1993), in
which in a combination study the increase in drug-induced nuclear
staining was not related to the dose of either carboplatin or
cisplatin. Togetherthese data suggestthat adduct levels aftercarbo-
platin aredeterminedprimarilyby factors otherthan drug exposure,
which could include drug uptake, reaction with glutathione orother
inactivation mechanisms and DNA repair (de Graeffet al, 1988).
As discussed above, Pt-DNA adduct levels in PBLs and tumour
response have been shown to be related in a number of studies
(Reed et al, 1986, 1987, 1990; Fichtinger-Schepman et al, 1990;
Ma et al, 1994). Iflow adduct levels in poor responders are due to
an intracellular factor in the PBLs then the same factor must be
operating in the tumour cells, i.e. the tumour cell is exhibiting a
host phenotype. The numbers of patients studied here were too
small to permit the relationship between adduct levels and
response to be studied, particularly as the Pt drugs formed only
part ofcomplex chemotherapy protocols and the disease types and
theirchemosensitivity varied widely (Table 1).
In conclusion, this study demonstrates that the variation in
Pt-DNA adduct formation seen in peripheral blood cells of chil-
dren treated with cisplatin and carboplatin is not related purely to
dose administered or the unbound drug AUC. There was a marked
difference in the levels and kinetics of DNA modification
produced by cisplatin and carboplatin treatment such that, after
standard clinical doses, cisplatin produced higher levels of
immunoreactive Pt-DNA adduct than carboplatin despite the
doses andAUCs forcarboplatinbeinghigherthan forcisplatin. All
ofthe children studied in this paper were receiving cisplatin and/or
carboplatin in combination with other cytotoxic agents and it was
not possible to study the relationship between Pt-DNA adduct
levels and response or toxicity. To define the relevance of the
Pt-DNA adduct levels determined in patients, further in vitro and
clinical studies of the relationship between toxicity, activity and
Pt-DNA adduct formation are warranted.
ABBREVIATIONS
BW, body weight; SA, surface area; DG, diagnosis; F, female; M,
male; OS, osteosarcoma; MFHC, malignant fibrous histiocytosis;
MOC, mucoepidermoid carcinoma of the parotid gland; NE,
neuroendocrine tumour; BSG, brainstem glioma; ME, medullo-
blastoma; PT, pineal teratoma; RPR, relapsed parameningeal rhab-
domyosarcoma; GL, glioma; PRPD, peritoneal relapse of pineal
dysgerminoma; NB, neuroblastoma; DOX, doxorubicin; CPA,
cyclophosphamide; VCR, vincristine; VP16, etoposide; COJEC,
treatment withcarboplatin, vincristine andVP16 onday 1, and with
cisplatin and vincristine on day 10; OPEC/OJEC, treatment with
cisplatin, vincristine, VP16 and cyclophosphamide on day 1 and
with carboplatin, vincristine, VP16 and cyclophosphamide on day
21. *Two values, the measured age, BW and SA at the time when
cisplatin andcarboplatin studies were performed respectively.
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